Enjie: "Enjie Convertible Bonds" recently transferred 1952 shares
Author:Daily Economic News Time:2022.07.04
Every time AI News, Enjie (SZ 002812, the latest price: 249.71 yuan) announced on July 4th that from April 1, 2022 to June 30, 2022 The decrease of the shares was about 130,000 yuan, a decrease of 1,272, and the number of to 1952 shares was 1952. As of the end of the second quarter of 2022, the amount of the remaining convertible bonds was about 454 million yuan, and the number of remaining convertible bonds was about 4.54 million.
From January to December 2021, the operating income of Enjie Co., Ltd. was: manufacturing accounted for 98.55%.
The chairman of Enjie is Paul Xiaoming Lee, male, 64 years old, and his academic background is a master's degree; the general manager is Li Xiaohua, male, 60 years old, and his academic background is a master's degree.
Daeda1997 "Single Stock Trends" reminder:
1. Ensijie shares increased by 9.4143 million shares in the north within the past 30 days, accounting for 1.30%of the proportion of circulation shares;
2. In the past 30 days, a total of 1 batch of institutions investigated Enjie's shares. The total number of institutions in total survey was 6.
For more stock trend information, please search for the WeChat public account "Daida", reply "Query", and receive free query permissions!
Each headline (NBDTOUTIAO) - "100,000 -piece investment consulting advertisements do not want to pick up"! How hot is the fan economy in the financial circle? The public account of 100,000 powder sells 2 million
(Reporter Wang Xiaobo)
Disclaimer: The content and data of this article are for reference only, do not constitute investment suggestions, and verify before use. Based on this, the risk is on its own.
Daily Economic News
- END -
Cultural Tourism Style Standard | Exclusive In -depth Research: State Cultural Industrial Park Construction Trends
A few days ago, the Ministry of Culture and Tourism issued the Opinions on Promoti...
Hongbo Medicine: Frequent changes in the top five customers
The one -stop comprehensive service provider of the new drug research and developm...